\
&
Contact us
\
&
Contact us
Published on | 3 months ago
ProgrammesThe European Rare Diseases Research Alliance (ERDERA) will launch its 2026 joint transnational call 'Resolving unsolved cases in rare genetic and non-genetic diseases' on 10 December 2025. The goal of this call is to solve Undiagnosed Rare Genetic diseases and to address complex, multifactorial Rare Non-Genetic diseases by identifying causative variants in patients with no molecular diagnosis after prior genetic or genomic testing and providing diagnostic clarity for conditions of unknown or mixed pathogenesis.
Research Foundation Flanders (FWO) plans to participate in this call. More information on available funding for researchers based in Flanders and on how to apply will be published on FWO's website once the call is launched. Deadline for the submission of pre-proposals is 12 February 2026. Questions on available funding by FWO? Contact europe@fwo.be.
More information on the call, its conditions and how to apply will be made available soon on the ERDERA dedicated webpage. Interested in applying? Join the information webinar on 16 December 2025 here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
